FRANKFURT, Germany and PRINCETON, N.J. and BANGALORE, India, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization...
-- Company Delivers Fourth Consecutive Quarter of U.S. Revenue Stabilization, Positive Fourth Quarter Cash Flow and Continued Progress on European...
Acquisition to enable creation of a fully integrated, enterprise-wide capability to discover, design and develop next-generation immunotherapies at scale by...
-- Fifth Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate the impact of subjects’...
New purpose-driven company founded to manage work comp care and costs in a timely and compassionate mannerEDINA, Minn., Jan. 10,...
First iPSC-derived commercially viable off-the-shelf islet combination product is advancing towards regulatory filing in 2024 for anticipated clinical trial authorization...
Despite Uncertainties, Survey Hints that Dealmaking Intensity Could Be Poised for a Rebound After a Year of InertiaMORRISVILLE, N.C., Jan....
-- Dr. Stewart Brings More Than 30 Years of Cardiometabolic Academic and Industry Experience to Amarin’s Board –- -- Ongoing...
WATERTOWN, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein...
Prenetics has completed the majority stake acquisition of ACT Genomics to spearhead its entry into to the US$80+ billion global...
After Five Years of Research, Cerē’s Physicians Introduce an Arousal Gel That Has Three Things Others Do Not - With...
LOS ANGELES, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Calibre Scientific is pleased to announce the acquisition of Dynalab Corp. (the “Company”), a...
Topline safety, antiviral effectiveness and pharmacokinetic (PK) data from a Phase 1b Study in China are released from the single...
Fourth Quarter revenue of $31.7 - $31.9 million representing growth of approximately 26%Fiscal Year 2022 revenue of $106.1 - $106.3...
NGM Bio’s three-pronged corporate strategy includes the following components:Focus internal clinical development efforts on solid tumor oncology portfolioGenerate next-generation biologics...
Company is on track to move into the clinic with its lead targeted therapeutics programSAN DIEGO, Jan. 09, 2023 (GLOBE...
-- Record revenue of $9M in 4QFY22; Increase of 191% over 4QFY21 -- BioXp® Revenue increased by 131% to $3M,...
Mid-stage and Pivotal Trials of ANX005, ANX007 and ANX1502 Poised to Achieve Numerous Catalysts in Multiple Disease Indications Well-Capitalized with...
- As of year-end 2022, more than 150 patients with NRG1 gene fusion positive (“NRG1+”) cancer have been treated with...
- Significant and rapid improvement in both signs and symptoms of TED after two infusions of 3 mg/kg, generally consistent...